Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Mar;29(3):313-21; quiz 322.
doi: 10.1038/eye.2015.1. Epub 2015 Feb 20.

Randomised clinical trial evaluating best-corrected visual acuity and central macular thickness after 532-nm subthreshold laser grid photocoagulation treatment in diabetic macular oedema

W Pei-Pei  1 , H Shi-Zhou  1 , T Zhen  1 , L Lin  1 , L Ying  1 , O Jiexiong  1 , Z Wen-Bo  1 , J Chen-Jin  1
Affiliations
Randomized Controlled Trial

Randomised clinical trial evaluating best-corrected visual acuity and central macular thickness after 532-nm subthreshold laser grid photocoagulation treatment in diabetic macular oedema

W Pei-Pei et al. Eye (Lond). 2015 Mar.

Abstract

Purpose: To compare best-corrected visual acuity (BCVA) and central macular thickness (CMT) after 532-nm subthreshold laser grid photocoagulation and threshold laser grid photocoagulation for the treatment of diabetic macular oedema (DME).

Patients and methods: Twenty-three patients (46 eyes) with binocular DME were enroled in this study. The two eyes of each patient were divided into a subthreshold photocoagulation group and a threshold photocoagulation group. The eyes of the subthreshold group underwent 532-nm patter scan laser system (PASCAL) 50% end point subthreshold laser grid photocoagulation therapy, whereas the threshold photocoagulation group underwent short-pulse grid photocoagulation with a 532-nm PASCAL system. BCVA and CMT were assessed in all patients before treatment, 7 days after treatment, and 1, 3, and 6 months after treatment.

Results: After grid photocoagulation, the mean BCVA improved in both the subthreshold group, and the threshold group, and the two groups did not differ statistically significantly from each other. Similarly, the macular oedema diminished in both groups after treatment, and the two groups did not differ statistically significantly from each other with regard to CMT.

Conclusion: Both 532-nm subthreshold laser grid photocoagulation and threshold laser grid photocoagulation can improve the visual acuity and reduce CMT in DME patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Mean BCVA at baseline and follow-ups. 1, subthreshold laser photocoagulation group; 2, threshold laser photocoagulation group. x axis: follow-up time points; y axis: mean BCVA of ETDRS visual chart. (b) Mean CMT at baseline and follow-ups. 1, subthreshold laser photocoagulation group; 2, threshold laser photocoagulation group. x axis: follow-up time points; y axis: BCVA of ETDRS visual chart.
Figure 2
Figure 2
Infrared imaging (above) and autofluorescence (below) of baseline and 6 months after grid pattern laser photocoagulation. OD: threshold photocoagulation; OS: subthreshold photocoagulation.
See this image and copyright information in PMC

References

    1. Diabetes. Fact sheet No. 312. [article online] 2009. Available at http://www.who.int/mediacentre/factsheets/fs312/en/ . Accessed 20 December 2009.
    1. Klein R. Retinopathy in a population-based study. Trans Am Ophthalmol Soc. 1992;90:561–594. - PMC - PubMed
    1. Klein R, Klein BE.Vision disorders in diabetes Diabetes in America2nd ed.Bethesda, MD, USA: National Institutes of Health; 1995293–338.NIH publication no. 95-1468.
    1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464–1474. - PubMed
    1. Diabetes Control and Complications Trial Research Group Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–661. - PubMed

Publication types

Substances